FDA approves new mRNA-based flu vaccine

The U.S. Food and Drug Administration has approved a new mRNA-based seasonal flu vaccine for people 50 and older, Moderna said this week.

The flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab

The Food and Drug Administration on Wednesday approved the first mRNA-based influenza vaccine, marking a milestone for the technology, which was first widely used during the COVID-19 pandemic. The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of se

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine  AP News

The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna.  The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the effec

After refusing to even review it, the FDA has approved Moderna's mRNA seasonal flu vaccine.

FDA Approves First mRNA Flu Vaccine For Older Adults  Forbes

The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.

FDA approves first mRNA-based flu vaccine  CNN

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Process  WSJ

The agency had initially refused to even review the application but reversed course after a public outcry.

The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.

Canada is now the second country to authorize a Phase I clinical trial for a Bundibugyo virus vaccine candidate after the U.K., according to federal officials in a news release.